ArticleCureus2025
Predictors of Remission in Graves' Disease Patients Treated With Antithyroid Drugs: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesGraves' disease (GD) is an autoimmune disorder characterized by excessive stimulation of the thyroid gland, resulting in hyperthyroidism. Antithyroid drugs (ATDs) are commonly used for its treatment, but the predictors of remission and factors associated with a positive response to ATD therapy are not fully understood.
methodsA retrospective study was conducted using medical records of 64 patients diagnosed with GD at a hospital in Saudi Arabia. Demographic characteristics, thyroid-related factors, ATD treatment details, and remission rates data were collected. Statistical analysis was performed using univariate association tests and multivariable logistic regression models.
resultsThe majority of participants were females, with a median age of 38 years. Smoking history was reported in 28.9% of patients. Methimazole (MMI) was the predominant ATD used. The remission rate with ATD treatment was 62.5%. In terms of predictors of remission, 50% of female participants achieved remission compared to 94.4% of male participants (p < 0.01). The body mass index was 26.4 in the remitted group compared to 30.4 in those not achieving remission (p = 0.028). The maximum TSH level while on treatment exhibited significant association as the remitted group had higher maximum TSH levels (median 6.5) compared to the non-remitted group (median 1.2) (p = 0.010).
conclusionThe study highlights the common use of MMI as the primary antithyroid drug and the positive remission outcomes in most patients. Male gender, lower BMI, and higher maximum TSH levels on treatment were predictors of remission. More research with larger samples and longer follow-up is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.